FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385800383> ?p ?o ?g. }

• W4385800383 endingPage "1855" @default.
• W4385800383 startingPage "1845" @default.
• W4385800383 abstract "After a brief period of dual antiplatelet therapy, P2Y12 inhibitor monotherapy in the absence of aspirin effectively reduces bleeding without increasing recurrent ischemia in patients undergoing percutaneous coronary intervention (PCI). In addition, early anti-inflammatory therapies may have clinical benefits in acute coronary syndrome (ACS) patients. The aim of this study was to investigate the feasibility of ticagrelor or prasugrel P2Y12 inhibitor monotherapy combined with colchicine immediately after PCI in patients with ACS. This was a proof-of-concept pilot trial. ACS patients treated with drug-eluting stents were included. On the day after PCI, low-dose colchicine (0.6 mg daily) was administered in addition to ticagrelor or prasugrel maintenance therapy, whereas aspirin therapy was discontinued. The primary outcome was any stent thrombosis at 3 months. The key secondary outcomes were platelet reactivity measured by the VerifyNow assay (Accriva) before discharge and a reduction in high-sensitivity C-reactive protein (hs-CRP) over 1 month. We enrolled 200 patients, 190 (95.0%) of whom completed the 3-month follow-up. The primary outcome occurred in 2 patients (1.0%): 1 definite and 1 probable stent thrombosis. The level of platelet reactivity overall was 27 ± 42 P2Y12 reaction units, and only 1 patient had high platelet reactivity (>208 P2Y12 reaction units). The hs-CRP levels decreased from 6.1 mg/L (IQR: 2.6-15.9 mg/L) at 24 hours after PCI to 0.6 mg/L (IQR: 0.4-1.2 mg/L) at 1 month (P < 0.001), and the prevalence of high-inflammation criteria (hs-CRP ≥2 mg/L) decreased from 81.8% to 11.8% (P < 0.001). In ACS patients undergoing PCI, it is feasible to discontinue aspirin therapy and administer low-dose colchicine on the day after PCI in addition to ticagrelor or prasugrel P2Y12 inhibitors. This approach is associated with favorable platelet function and inflammatory profiles. (Mono Antiplatelet and Colchicine Therapy [MACT]; NCT04949516)" @default.
• W4385800383 created "2023-08-15" @default.
• W4385800383 creator A5015160612 @default.
• W4385800383 creator A5037954844 @default.
• W4385800383 creator A5040418600 @default.
• W4385800383 creator A5041477606 @default.
• W4385800383 creator A5051081776 @default.
• W4385800383 creator A5053997401 @default.
• W4385800383 creator A5071329655 @default.
• W4385800383 creator A5076394835 @default.
• W4385800383 date "2023-08-01" @default.
• W4385800383 modified "2023-09-27" @default.
• W4385800383 title "P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients" @default.
• W4385800383 cites W117883744 @default.
• W4385800383 cites W1893844572 @default.
• W4385800383 cites W1990018236 @default.
• W4385800383 cites W2036632357 @default.
• W4385800383 cites W2048278363 @default.
• W4385800383 cites W2073836848 @default.
• W4385800383 cites W2087150869 @default.
• W4385800383 cites W2099172760 @default.
• W4385800383 cites W2102785524 @default.
• W4385800383 cites W2105735830 @default.
• W4385800383 cites W2122779695 @default.
• W4385800383 cites W2162435142 @default.
• W4385800383 cites W2511861509 @default.
• W4385800383 cites W2515533568 @default.
• W4385800383 cites W2522665294 @default.
• W4385800383 cites W2593571361 @default.
• W4385800383 cites W2607096599 @default.
• W4385800383 cites W2748400555 @default.
• W4385800383 cites W2752033985 @default.
• W4385800383 cites W2888458270 @default.
• W4385800383 cites W2895567195 @default.
• W4385800383 cites W2953479758 @default.
• W4385800383 cites W2955952534 @default.
• W4385800383 cites W2976166882 @default.
• W4385800383 cites W2986700515 @default.
• W4385800383 cites W3005964164 @default.
• W4385800383 cites W3021331407 @default.
• W4385800383 cites W3035351100 @default.
• W4385800383 cites W3081761942 @default.
• W4385800383 cites W3082165044 @default.
• W4385800383 cites W3087046564 @default.
• W4385800383 cites W3132730908 @default.
• W4385800383 cites W3137618585 @default.
• W4385800383 cites W3158220026 @default.
• W4385800383 cites W3162195278 @default.
• W4385800383 cites W4200601666 @default.
• W4385800383 cites W4214943375 @default.
• W4385800383 cites W4310055968 @default.
• W4385800383 cites W4319059953 @default.
• W4385800383 doi "https://doi.org/10.1016/j.jcin.2023.05.035" @default.
• W4385800383 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37587591" @default.
• W4385800383 hasPublicationYear "2023" @default.
• W4385800383 type Work @default.
• W4385800383 citedByCount "1" @default.
• W4385800383 countsByYear W43858003832023 @default.
• W4385800383 crossrefType "journal-article" @default.
• W4385800383 hasAuthorship W4385800383A5015160612 @default.
• W4385800383 hasAuthorship W4385800383A5037954844 @default.
• W4385800383 hasAuthorship W4385800383A5040418600 @default.
• W4385800383 hasAuthorship W4385800383A5041477606 @default.
• W4385800383 hasAuthorship W4385800383A5051081776 @default.
• W4385800383 hasAuthorship W4385800383A5053997401 @default.
• W4385800383 hasAuthorship W4385800383A5071329655 @default.
• W4385800383 hasAuthorship W4385800383A5076394835 @default.
• W4385800383 hasConcept C126322002 @default.
• W4385800383 hasConcept C164705383 @default.
• W4385800383 hasConcept C2777028646 @default.
• W4385800383 hasConcept C2777628954 @default.
• W4385800383 hasConcept C2777698277 @default.
• W4385800383 hasConcept C2777849778 @default.
• W4385800383 hasConcept C2778583881 @default.
• W4385800383 hasConcept C2780400711 @default.
• W4385800383 hasConcept C2780890252 @default.
• W4385800383 hasConcept C45393284 @default.
• W4385800383 hasConcept C49059817 @default.
• W4385800383 hasConcept C500558357 @default.
• W4385800383 hasConcept C71924100 @default.
• W4385800383 hasConcept C90924648 @default.
• W4385800383 hasConceptScore W4385800383C126322002 @default.
• W4385800383 hasConceptScore W4385800383C164705383 @default.
• W4385800383 hasConceptScore W4385800383C2777028646 @default.
• W4385800383 hasConceptScore W4385800383C2777628954 @default.
• W4385800383 hasConceptScore W4385800383C2777698277 @default.
• W4385800383 hasConceptScore W4385800383C2777849778 @default.
• W4385800383 hasConceptScore W4385800383C2778583881 @default.
• W4385800383 hasConceptScore W4385800383C2780400711 @default.
• W4385800383 hasConceptScore W4385800383C2780890252 @default.
• W4385800383 hasConceptScore W4385800383C45393284 @default.
• W4385800383 hasConceptScore W4385800383C49059817 @default.
• W4385800383 hasConceptScore W4385800383C500558357 @default.
• W4385800383 hasConceptScore W4385800383C71924100 @default.
• W4385800383 hasConceptScore W4385800383C90924648 @default.
• W4385800383 hasIssue "15" @default.
• W4385800383 hasLocation W43858003831 @default.
• W4385800383 hasLocation W43858003832 @default.

• next